Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

27277studies shown

Showing 6,133-6,144 of 27,277

CompletedNCT01157351

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

Official study title

A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated

This study has finished and is no longer accepting participants.

Multiple locations, including Bullhead City

SchizophreniaMedication studyAges 18–65

Countries: United States
Sponsor: Janssen Scientific Affairs, LLC

View study

TerminatedNCT02389712

16-week Comparative Effectiveness study of Lamotrigine vs. Fluoxetine for Depression in bipolarity

Official study title

16-week Open Randomized Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression: Pharmacogenomic and Biomarker Predictors of Response

This study ended early.

In Rochester

Bipolarity, DepressionMedication studyAges 18–65

Countries: United States
Sponsor: Mayo Clinic

View study

CompletedNCT06880328

18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in people with Schizophrenia

Official study title

18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET), Randomized, Double-blind, Crossover Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With 150mg of RO6889450 or Placebo in Patients With Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Glendale

SchizophreniaMedication studyAges 18–50

Countries: United States
Sponsor: Hoffmann-La Roche

View study

CompletedNCT03902613

18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolarity

Official study title

18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder

This study has finished and is no longer accepting participants.

In New York

Bipolarity, DepressionMedication studyAges 18–50

Countries: United States
Sponsor: New York State Psychiatric Institute

View study

CompletedNCT07097025

2-Year Study of Vagus Nerve Stimulation for Higher-Grade Treatment-Resistant Depression: Clinical Outcomes and Policy Recommendation

Official study title

Efficacy and Safety of Vagus Nerve Stimulation Treatment in Treatment Resistant Depression

This study has finished and is no longer accepting participants.

Multiple locations, including Bnei Brak

Depression, BipolarityObservational studyAges 18+

Countries: Israel
Sponsor: Dr.Yoav Domany

View study

CompletedNCT01404208

2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD

This study has finished and is no longer accepting participants.

In Boston

OCDMedication studyAges 7–17

Countries: United States
Sponsor: Massachusetts General Hospital (Hospital / academic medical center)

View study

CompletedNCT01193205

20 Weeks DBT Group Skills Training Study

Official study title

Evaluating the Effectiveness of Dialectical Behaviour Skills Training for Suicidality in Borderline Personality Disorder

This study has finished and is no longer accepting participants.

In Toronto

Personality disordersBehavioural studyAges 18–60

Countries: Canada
Sponsor: Centre for Addiction and Mental Health (Hospital / academic medical center)

View study

TerminatedNCT01568216

20101299: Study Effect of AMG 747 on Schizophrenia Negative Symptoms

Official study title

"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms"

This study ended early.

Multiple locations, including Anaheim

SchizophreniaMedication studyAges 18–60

Countries: United States, Australia, Canada, + 4 others
Sponsor: Amgen

View study

TerminatedNCT01568229

20110165: Study Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)

Official study title

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms

This study ended early.

Multiple locations, including Little Rock

SchizophreniaMedication studyAges 18–60

Countries: United States, France, United Kingdom, + 3 others
Sponsor: Amgen

View study

CompletedNCT00818298

24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study

This study has finished and is no longer accepting participants.

In Toronto

SchizophreniaMedication studyAges 18–60

Countries: Canada
Sponsor: Centre for Addiction and Mental Health (Hospital / academic medical center)

View study

TerminatedEUCTR 2005-005502-23

26-week open-label extension study evaluating the safety and tolerability of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.

This study ended early.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Germany

SchizophreniaHistorical research record

Countries: Germany, Sweden
Sponsor: Pfizer AB

View study

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.